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The blood supply in industrialized countries
is safer than ever. However, blood (a human tis-
sue) is a natural vehicle for transmission of in-
fectious agents. In recent years, numerous
pathogens have emerged in the United States
and worldwide with the potential to affect the
safety of the blood supply.
International Movement of Infectious
Agents
Movement of transfusable blood and blood
components between countries is relatively un-
common. However, infectious agents can cross
international borders through immigration or
travel. For example, malaria is an important prob-
lem in much of the world, with an estimated 300
to 500 million cases per year. On average, 1,000
cases are reported each year in the United States,
most in persons who travel to malaria-endemic
areas. Only a small number of cases (approxi-
mately three per year) are transmitted by expo-
sure to infected blood products. Current measures
(which temporarily defer donors with a history of
origin in a malarious country, clinical malaria, or
travel to malaria-endemic areas) appear to be ef-
fective. Similarly, Chagas disease, a vector-borne
disease caused by the parasite Trypanosoma cruzi,
is endemic in parts of Central and South America
and Mexico, where infected persons can transmit
the disease through transfusion. The immigration
of millions of persons from T. cruzi–endemic ar-
eas and increased international travel have raised
concerns about the potential for transfusion-trans-
mitted Chagas disease. Five cases of T. cruzi trans-
mission from transfusions have been reported in
North America. Recent seroprevalence studies
showed that approximately 0.1% of blood donors
likely to have been born in or have traveled to
disease-endemic countries were seropositive for
T. cruzi. Moreover, American Red Cross studies
of recipients of T. cruzi–seropositive blood and
blood products showed no evidence of transmis-
sion. Finally, variant forms of recognized patho-
gens can potentially affect the safety of the blood
supply. Current serologic tests do not consistently
detect HIV-1 group O infections, which are com-
mon in some West and Central African countries
but very rare (two cases) in the United States.
Efforts are under way to modify existing serologic
tests to improve detection of group O strains with-
out compromising sensitivity for the predominant
group M viruses. As an interim measure, the Food
and Drug Administration has recommended that
donors at increased risk for HIV-1 group O on the
basis of residence and risk exposure be deferred
from donating blood or plasma.
Creutzfeldt-Jakob Disease and Blood
Safety
Risk for transmission by transfusion is poorly
characterized for a number of emerging agents.
One of these is Creutzfeldt-Jakob disease (CJD),
a rare, fatal neurodegenerative disease believed
to be caused by an abnormal form of prion pro-
tein. CJD has been transmitted iatrogenically
through human pituitary-derived growth hor-
mones, human dura mater grafts, corneal trans-
plants, and contaminated surface electroencepha-
logram electrodes and neurosurgical instruments.
Incubation was as long as 30 years in some cases.
Concerns regarding bloodborne transmission of
the CJD agent derive primarily from laboratory
studies, including animal models, which suggest
such a potential. However, no proven cases of blood
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transmission are reported in humans, and accu-
mulating epidemiologic information (surveil-
lance, follow-up of recipients of blood from do-
nors who subsequently developed CJD, and
case-control data) indicates that the risk (if
any) for transmission of CJD by blood prod-
ucts is extremely small. At present, CJD is
considered a remote, theoretical risk.
In March 1996, health officials in the United
Kingdom announced that the agent responsible
for the decade-old bovine spongiform encephal-
opathy epizootic might have spread to humans.
As of March 1998, 24 persons have been reported
with this apparently new variant form of CJD
(nvCJD). The possibility of nvCJD transmission
through the blood supply has been debated. Cur-
rently, this risk is theoretical. However, because
the infectious agent of nvCJD is new in humans,
it may present risks that differ from those of clas-
sic CJD. In addition, important differences have
been noted in the two diseases. For example, hu-
man spleen and tonsil tissues contain abnormal
prion protein in nvCJD but not in classic CJD. In
view of this uncertainty, U.K. health officials have
undertaken a conservative approach, including
1) withdrawal of blood products donated by per-
sons subsequently confirmed or strongly sus-
pected to have nvCJD; 2) discontinuation of the
use of British plasma in plasma-derived prod-
ucts; and 3) consideration of leukodepletion of
all blood donations, in view of experimental
studies suggesting that B lymphocytes may play
a role in the development of scrapie.
Tick-Borne Agents and Transfusion Risk
In the United States, the most commonly re-
ported transfusion-associated tickborne infection
is babesiosis. At least 21 reported cases of babe-
siosis, mostly caused by Babesia microti but also
by the more recently recognized WA1-type Babe-
sia parasite, have been transmitted by transfu-
sion of blood from asymptomatic infected blood
donors. With the expansion of deer populations
(natural host of B. microti) in the northeastern
United States, the incidence of transfusion-trans-
mitted babesiosis may increase. The tick vector
and animal reservoir of the Babesia more recently
found in the northwestern and western United
States remain to be defined. The parasite survives
blood-banking conditions and is transmissible by
transfusion of red blood cells and platelet concen-
trates. Although babesiosis classically causes a
febrile illness with hemolytic anemia, infection
can also cause chronic asymptomatic or mildly
symptomatic parasitemia. Recent studies suggest
that untreated persons have evidence of B. microti
DNA for longer periods, despite mild or absent
symptoms, and may transmit infection for months
or possibly longer. The potential for transmission
of other tick-borne agents is unclear. Like babe-
siosis, Lyme disease or ehrlichiosis (caused by an
obligate intracellular gram-negative rickettsia)
may be asymptomatic or mildly symptomatic; spi-
rochetemia or rickettsemia can precede prodro-
mal symptoms by 24 to 72 hours, making trans-
mission by transfusion a possibility. One case of
transfusion-transmitted Rocky Mountain spotted
fever has been reported.
Summary
Since blood is a biologic product, it is unlikely
that the risk for transfusion-transmitted infection
will ever be reduced to zero. The approach to
emerging infections associated with transfusion
of blood and blood products includes assessing the
transmissibility of the agent by this route; devel-
oping effective prevention strategies, including
screening tests and donor deferral policies; im-
proving viral and bacterial inactivation proce-
dures; and surveillance for known, as well as
emerging and poorly characterized, transfusion-
transmitted agents. Vigilance is needed to help
ensure proper balance between safety and the
availability of blood. Finally, vigilance needs to
extend to the developing world, where the ba-
sic elements to reduce transfusion-transmitted
infections and systems of disease surveillance
are often not available.